Adverum Biotechnologies Announces Closing of $69 Million Public Offering

- February 13th, 2018

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced underwritten public offering of its common stock.  Adverum Biotechnologies sold 10,222,235 shares of its common stock, including 1,333,335 shares pursuant to the full exercise of the underwriters’ option, at … Continued

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the closing of its previously announced underwritten public offering of its common stock.  Adverum Biotechnologies sold 10,222,235 shares of its common stock, including 1,333,335 shares pursuant to the full exercise of the underwriters’ option, at a price to the public of $6.75 per share.

As quoted in the press release:

The gross proceeds from this offering were $69.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Adverum Biotechnologies.  All of the shares of common stock were offered by Adverum Biotechnologies.

Cowen and Piper Jaffray & Co. acted as joint book-running managers for the offering.  Raymond James acted as lead manager.

Click here to read the full press release.

Biotech Stocks in 2018


Find out how the market will look this year


Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *